Complications of cirrhosis. A 50 years flashback

References

• DJLeeming, MAKarsdal, IByrjalsen, FBendtsen, JTrebicka, MJNielsen, et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther 2013;38:1086–96.
   PubMed Web of Science ®Google Scholar
• EATsochatzis, JBosch, AKBurroughs. Liver cirrhosis. Lancet 2014;383:1749–1761.
   PubMed Web of Science ®Google Scholar
• MKDam, TFlensborg-Madsen, MEliasen, UBecker, JSTolstrup. Smoking and risk of liver cirrhosis: a population-based cohort study. Scand J Gastroenterol 2013;48:585–91.
   PubMed Web of Science ®Google Scholar
• JEPuche, YSaiman, SLFriedman. Hepatic stellate cells and liver fibrosis. Compr Physiol 2013;3:1473–92.
   PubMed Web of Science ®Google Scholar
• MFernandez. Molecular pathophysiology of portal hypertension. Hepatology 2014. [Epub ahead of print].
   Web of Science ®Google Scholar
• YIwakiri, VShah, DCRockey. Vascular pathobiology in chronic liver disease and cirrhosis - Current status and future directions. J Hepatol 2014;61:912–24.
   PubMed Web of Science ®Google Scholar
• TMBusk, FBendtsen, HJNielsen, VJensen, NBrunner, SMøller. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scand J Gastroenterol 2014;49:1103–10.
   PubMed Web of Science ®Google Scholar
• JDVorobioff, RJGroszmann. Prevention of portal hypertension: From variceal development to clinical decompensation. Hepatology 2015;61:375–81.
   PubMed Web of Science ®Google Scholar
• MBuck, GGarcia-Tsao, RJGroszmann, CStalling, NDGrace, AKBurroughs, et al. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients. Hepatology 2014;59:1052–9.
   PubMed Web of Science ®Google Scholar
• TPAlmdal, TIASørensen. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. Hepatology 1991;13:650–5.
   PubMed Web of Science ®Google Scholar
• SAGunnarsdottir, ROlsson, SOlafsson, NCariglia, JWestin, BThjodleifsson, et al. Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes. Scand J Gastroenterol 2009;44:984–93.
   PubMed Web of Science ®Google Scholar
• FADam, OBSchaffalitzky de Muckadell, LATouborg. Incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol 2012;47:702–9.
   PubMed Web of Science ®Google Scholar
• JWHaukeland, ILorgen, LTSchreiner, SOFrigstad, BBrandsaeter, KBjorø, et al. Incidence rates and causes of cirrhosis in a Norwegian population. Scand J Gastroenterol 2007;42:1501–8.
   PubMed Web of Science ®Google Scholar
• SOlafsson, ESBjornsson. Differences and similarities in the etiology and the incidence of cirrhosis in the Nordic countries. Scand J Gastroenterol 2013;48:509–10.
   PubMed Web of Science ®Google Scholar
• HYtting, SMøller, HJHenrik, KLarsen, FBendtsen. Prognosis in patients with cirrhosis and mild portal hypertension. Scand J Gastroenterol 2006;41:1446–53.
   PubMed Web of Science ®Google Scholar
• LHobolth, AKrag, FBendtsen. The recent reduction in mortality from bleeding oesophageal varices is primarily observed from Days 1 to 5. Liver Int 2010;30:455–62.
   PubMed Web of Science ®Google Scholar
• MTKitson, SKRoberts, JCColman, EPaul, PButton, WKemp. Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications. Scand J Gastroenterol 2015. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• SMøller, JHHenriksen. The systemic circulation in cirrhosis. In PGines, VArroyo, JRodes, RWSchrier, editors. Ascites and renal dysfunction in liver disease. 2nd edition. Malden: Blackwell; 2005. p 139–55.
   Google Scholar
• SMøller, JHHenriksen, FBendtsen. Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World J Gastroenterol 2014;20:15499–517.
   PubMed Web of Science ®Google Scholar
• LHobolth, FBendtsen, SMøller. Indications for portal pressure measurement in chronic liver disease. Scand J Gastroenterol 2012;47:887–92.
   PubMed Web of Science ®Google Scholar
• SMøller, JHHenriksen. Cardiovascular complications of cirrhosis. Gut 2008;57:268–78.
   PubMed Web of Science ®Google Scholar
• SMøller, FBendtsen, JHHenriksen. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Scand J Gastroenterol 2005;40:491–500.
   PubMed Web of Science ®Google Scholar
• PAngeli, ASanyal, SMøller, CAlessandria, AGadano, RKim, et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int 2013;33:16–23.
   Google Scholar
• JCGarcia-Pagan, JGracia-Sancho, JBosch. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012;57:458–61.
   PubMed Web of Science ®Google Scholar
• JSJohansen, SMøller, PAPrice, FBendtsen, JJunge, CGarbarsch, et al. Plasma YKL-40: A new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997;32:582–90.
   PubMed Web of Science ®Google Scholar
• SLFriedman. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125–72.
   PubMed Web of Science ®Google Scholar
• JBosch, JGAbraldes, MFernandez, JCGarcia-Pagan. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol 2010;53:558–67.
   PubMed Web of Science ®Google Scholar
• LDDeLeve. Liver sinusoidal endothelial cells and liver regeneration. J Clin Invest 2013;123:1861–6.
   PubMed Web of Science ®Google Scholar
• FBraet, EWisse. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002;1:1.
   PubMedGoogle Scholar
• JGAbraldes, YIwakiri, MLoureiro-Silva, OHaq, WCSessa, RJGroszmann. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006;290:G980–7.
   PubMed Web of Science ®Google Scholar
• SMøller, LHobolth, CWinkler, FBendtsen, EChristensen. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011;60:1254–9.
   PubMed Web of Science ®Google Scholar
• OLemoine, AHadengue, RMoreau, PSogni, TSoupison, SYang, et al. Relationship between portal pressure, esophageal varices, and variceal bleeding on the basis of the stage and cause of cirrhosis. Scand J Gastroenterol 1997;32:731–5.
   PubMed Web of Science ®Google Scholar
• RJGroszmann, JGAbraldes. Portal hypertension: from bedside to bench. J Clin Gastroenterol 2005;39:S125–30.
   PubMed Web of Science ®Google Scholar
• JLMadsen, SBSøndergaard, SMøller. Meal-induced changes in splanchnic blood flow and oxygen uptake in middle-aged healthy humans. Scand J Gastroenterol 2006;41:87–92.
   PubMed Web of Science ®Google Scholar
• AKrag, LSimonsen, JHHenriksen, LOttesen, FBendtsen. Effect of meal and propranolol on whole body and splanchnic oxygen consumption in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol 2006;291:G8–15.
   PubMed Web of Science ®Google Scholar
• FBendtsen, JHHenriksen, TIASørensen. Long-term effects of oral propranolol on spanchnic and systemic haemdynamics in patients with cirrhosis and oesophageal varices. Scand J Gastroenterol 1991;26:933–9.
   PubMed Web of Science ®Google Scholar
• NKimer, MFeineis, SMøller, FBendtsen. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Scand J Gastroenterol 2014;50:129–37.
   PubMed Web of Science ®Google Scholar
• LSEriksson, TBrundin, CSöderlund, JWahren. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987;22:919–25.
   PubMed Web of Science ®Google Scholar
• MKiszka-Kanowitz, JHHenriksen, EFHansen, SMøller, FBendtsen. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol 2004;39:486–92.
   PubMed Web of Science ®Google Scholar
• AKrag, SMøller, JHHenriksen, FBendtsen. Effects of a single dose of terlipressin on transcutaneous oxygen pressures. Scand J Gastroenterol 2010;45:953–8.
   PubMed Web of Science ®Google Scholar
• BLavina, JGracia-Sancho, ARodriguez-Vilarrupla, YChu, DDHeistad, JBosch, et al. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut 2009;58:118–25.
   PubMed Web of Science ®Google Scholar
• FBendtsen, LTheil Skovgaard, TIASørensen, PMatzen. Agreement among multiple observers on endoscopic diagnosis of esophageal varices before bleeding. Hepatology 1990;11:341–7.
   PubMed Web of Science ®Google Scholar
• Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988;319:983–9.
   PubMed Web of Science ®Google Scholar
• MMerli, GNicolini, SAngeloni, VRinaldi, ADe Santis, CMerkel, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003;38:266–72.
   PubMed Web of Science ®Google Scholar
• FBendtsen, AKrag, SMøller. Treatment of acute variceal bleeding. Dig Liver Dis 2008;40:328–36.
   PubMedGoogle Scholar
• DLebrec, ONouel, MCorbic, JPBenhamou. Propranolol-a medical treatment for portal hypertension? Lancet 1980;2:180–2.
   PubMed Web of Science ®Google Scholar
• FBendtsen, JHHenriksen, TIASørensen. Propranolol and haemodynamic response in cirrhosis. J Hepatol 1991;13:144–8.
   PubMed Web of Science ®Google Scholar
• EFHansen, FBendtsen, KBrinch, SMøller, JHHenriksen, UBecker. Endoscopic Doppler ultrasound for measurement of azygos blood flow. Validation against thermodilution and assessment of pharmacological effects of terlipressin in portal hypertension. Scand J Gastroenterol 2001;36:318–25.
   PubMed Web of Science ®Google Scholar
• FBendtsen, JHHenriksen, TIASørensen, NJChristensen. Effect of oral propranolol on circulating catecholamines in cirrhosis: relationship to severity of liver disease and splanchnic haemodynamics. J Hepatol 1990;10:198–204.
   PubMed Web of Science ®Google Scholar
• FBendtsen, NJChristensen, TIASørensen, JHHenriksen. Effect of oral propranolol administration on azygos, renal and hepatic uptake and output of catecholamines in cirrhosis. Hepatology 1991;14:237–43.
   PubMed Web of Science ®Google Scholar
• Sclerotherapy after first variceal hemorrhage in cirrhosis. A randomized multicenter trial. The Copenhagen Esophageal Varices Sclerotherapy Project. N Engl J Med 1984;311:1594–600.
   PubMed Web of Science ®Google Scholar
• The PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: A randomized multicenter trial. Hepatology 1991;14:1016–24.
   PubMed Web of Science ®Google Scholar
• GD’Amico, LPagliaro, JBosch. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475–505.
   PubMed Web of Science ®Google Scholar
• LLGluud, SKlingenberg, DNikolova, CGluud. Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol 2007;102:2842–8.
   PubMed Web of Science ®Google Scholar
• LHobolth, SMøller, HGronbaek, KRoelsgaard, FBendtsen, HEFeldager. Carvedilol or propranolol in portal hypertension? A randomized comparison. Scand J Gastroenterol 2012;47:467–74.
   PubMed Web of Science ®Google Scholar
• DYGraham, JLacey Smith. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800–9.
   PubMed Web of Science ®Google Scholar
• ARabøl, EJuhl, ASchmidt, KWinkler. The effect of vasopressin and triglycyl lysine vasopressin (glypressin) on the splanchnic circulation in cirrhotic patients with portal hypertension. Digestion 1976;14:285–9.
   PubMed Web of Science ®Google Scholar
• SMøller, EFHansen, UBecker, KBrinch, JHHenriksen, FBendtsen. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000;20:51–9.
   PubMedGoogle Scholar
• CSöderlund, IMagnusson, STorngren, LLundell. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo- controlled trial. Scand J Gastroenterol 1990;25:622–30.
   PubMed Web of Science ®Google Scholar
• GIoannou, JDoust, DCRockey. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003:CD002147.
   PubMedGoogle Scholar
• EBjörnsson, LAabakken, SOlafsson, FBendtsen. Are specific guidelines necessary for treatment of esophageal varices in the Nordic countries? Scand J Gastroenterol 2009;44:1037–47.
   PubMed Web of Science ®Google Scholar
• AKrag, TBorup, SMøller, FBendtsen. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther 2008;25:1105–40.
   PubMed Web of Science ®Google Scholar
• AKrag, FBendtsen, EBPedersen, NHHolstein-Rathlou, SMøller. Effects of terlipressin on the aquaretic system - evidence of antidiuretic effects. Am J Physiol Renal Physiol 2008;295:F1295–300.
   PubMed Web of Science ®Google Scholar
• MWells, NChande, PAdams, MBeaton, MLevstik, EBoyce, et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 2012;35:1267–78.
   PubMed Web of Science ®Google Scholar
• LLaine, DCook. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995;123:280–7.
   PubMed Web of Science ®Google Scholar
• JHegnhøj, JRAndersen, JOJarlov, FBendtsen, HSRasmussen. Bacteremia after injection sclerotherapy of oesophageal varices. Liver 1988;8:167–71.
   PubMedGoogle Scholar
• RJalan, JFernandez, RWiest, BSchnabl, RMoreau, PAngeli, et al. Bacterial infections in cirrhosis. A position statement based on the EASL Special Conference 2013. J Hepatol 2014;60:1310–24.
   PubMed Web of Science ®Google Scholar
• KSoares-Weiser, MBrezis, RTur-Kaspa, MPaul, JYahav, LLeibovici. Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials. Scand J Gastroenterol 2003;38:193–200.
   PubMed Web of Science ®Google Scholar
• EEjlersen, TMelsen, JIngerslev, RBAndreasen, HVilstrup. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001;36:1081–5.
   PubMed Web of Science ®Google Scholar
• FBendtsen, GD’amico, ERusch, Rde Franchis, PKAndersen, DLebrec, et al. Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials. J Hepatol 2014;61:252–9.
   PubMed Web of Science ®Google Scholar
• MSSozio, NChalasani. Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events. Hepatology 2014;60:1786–8.
   PubMedGoogle Scholar
• JCGarcia-Pagan, KCaca, CBureau, WLaleman, BAppenrodt, ALuca, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370–9.
   PubMed Web of Science ®Google Scholar
• RGonzalez, JZamora, JGomez-Camarero, LMMolinero, RBanares, AAlbillos. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 2008;149:109–22.
   PubMed Web of Science ®Google Scholar
• JHHenriksen. The ’overflow’ theory of ascites formation: a fading concept? Scand J Gastroenterol 1983;18:833–7.
   PubMed Web of Science ®Google Scholar
• LBuo, TSKarlsrud, GDyrhaug, MBJacobsen, HBell, HTJohansen, et al. Differential diagnosis of human ascites: inhibitors of the contact system and total proteins. Scand J Gastroenterol 1993;28:777–82.
   PubMed Web of Science ®Google Scholar
• CHomann, EChristensen, PSchlichting, EKPhilipsen, NAGraudal, PGarred. Ascites fluid and plasma calprotectin concentrations in liver disease. Scand J Gastroenterol 2003;38:415–20.
   PubMed Web of Science ®Google Scholar
• EKalaitzakis, JEJohansson, IBjarnason, EBjörnsson. Intestinal permeability in cirrhotic patients with and without ascites. Scand J Gastroenterol 2006;41:326–30.
   PubMed Web of Science ®Google Scholar
• SMøller, JHHenriksen, FBendtsen. Ascites: pathogenesis and therapeutic principles. Scand J Gastroenterol 2009;44:902–11.
   PubMed Web of Science ®Google Scholar
• JHHenriksen. Colloid osmotic pressure in decompensated cirrhosis. A ‘mirror image’ of portal venous hypertension. Scand J Gastroenterol 1985;20:170–4.
   PubMed Web of Science ®Google Scholar
• JHHenriksen, HRing-Larsen, NJChristensen. Circulating noradrenaline and central haemodynamics in patients with cirrhosis. Scand J Gastroenterol 1985;20:1185–90.
   PubMed Web of Science ®Google Scholar
• PGentilini, FVizzutti, AGentilini, MZipoli, MFoschi, RGRomanelli. Update on ascites and hepatorenal syndrome. Dig Liver Dis 2002;34:592–605.
   PubMedGoogle Scholar
• RWSchrier. Decreased effective blood volume in edematous disorders: what does this mean? J Am Soc Nephrol 2007;18:2028–31.
   PubMed Web of Science ®Google Scholar
• VArroyo, JColmenero. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38:S69–89.
   PubMed Web of Science ®Google Scholar
• JHHenriksen, KWinkler. Transvascular escape rate of albumin in liver cirrhosis, and its possible role in formation of ascites. Scand J Gastroenterol 1977;12:877–84.
   PubMed Web of Science ®Google Scholar
• JHHenriksen, SMøller. Alterations of hepatic and splanchnic microvascular exchange in cirrhosis: Local factors in the formation of ascites. In PGines, VArroyo, JRodes, RWSchrier, editors. Ascites and renal dysfunction in liver disease. 2nd edition. Malden: Blackwell; 2005. p 174–85.
   Google Scholar
• JHHenriksen, OSiemssen, JJKrintel, AMalchow-Moller, FBendtsen, HRing-Larsen. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. J Hepatol 2001;34:53–60.
   PubMed Web of Science ®Google Scholar
• NKimer, JPGøtze, FBendtsen, SMøller. New vasoactive peptides in cirrhosis: Organ extraction and relation to the vasodilatory state. Eur J Clin Invest 2014;44:441–52.
   PubMed Web of Science ®Google Scholar
• SMøller, FBendtsen, JHHenriksen. Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume. Scand J Gastroenterol 2006;41:451–8.
   PubMed Web of Science ®Google Scholar
• RWiest. Splanchnic and systemic vasodilation: the experimental models. J Clin Gastroenterol 2007;41:S272–87.
   PubMed Web of Science ®Google Scholar
• MBernardi, PCaraceni. Pathogenesis of ascites and hepatorenal syndrome:altered haemodynamics and neurohumoral systems. In ALGerbes, UBeuers, DJungst, GPape, MSackmann, TSauerbruch, editors. Hepatology 2000. Falk symposium 117. Dordrecht: Kluwer Academic Publishers, 2001. p 185–203.
   Google Scholar
• CSöderman, ALeone, VFurst, MGPersson. Endogenous nitric oxide in exhaled air from patients with liver cirrhosis. Scand J Gastroenterol 1997;32:591–7.
   PubMed Web of Science ®Google Scholar
• SMøller, FBendtsen, SSchifter, JHHenriksen. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis. Scand J Gastroenterol 1996;31:928–33.
   PubMed Web of Science ®Google Scholar
• JHHenriksen, VGulberg, ALGerbes, FBendtsen, SMøller. Increased arterial compliance in cirrhosis is related to decreased arterial C-type natriuretic peptide, but not to atrial natriuretic peptide. Scand J Gastroenterol 2003;38:559–64.
   PubMed Web of Science ®Google Scholar
• SMøller, FBendtsen, JHHenriksen. Effect of beta-adrenergic blockade on elevated arterial compliance and low systemic vascular resistance in cirrhosis. Scand J Gastroenterol 2001;36:653–7.
   PubMed Web of Science ®Google Scholar
• SMøller, VGulberg, UBecker, ALGerbes, JHHenriksen. Elevated arterial compliance in patients with cirrhosis is not related to arterial endothelin-1. Scand J Gastroenterol 2002;37:1064–9.
   PubMed Web of Science ®Google Scholar
• GFernandez-Esparrach, ASanchez-Fueyo, PGines, JUriz, LQuinto, PJVentura, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46–52.
   PubMed Web of Science ®Google Scholar
• PGines, ACardenas, VArroyo, JRodes. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646–54.
   PubMed Web of Science ®Google Scholar
• KPMoore, FWong, PGines, MBernardi, AOchs, FSalerno, et al. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258–66.
   PubMed Web of Science ®Google Scholar
• PGines, PAngeli, KLenz, SMøller, KMoore, RMoreau, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397–417.
   PubMed Web of Science ®Google Scholar
• HRing-Larsen, JHHenriksen, CWilken, JClausen, HPals, NJChristensen. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J 1986;292:1351–3.
   PubMed Web of Science ®Google Scholar
• FSalerno, CCamma, MEnea, MRossle, FWong. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007;133:825–34.
   PubMed Web of Science ®Google Scholar
• AKrag, SMøller, JHHenriksen, NHHolstein-Rathlou, FSLarsen, FBendtsen. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007;46:1863–71.
   PubMed Web of Science ®Google Scholar
• AKrag, FBendtsen, JHHenriksen, SMøller. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105–10.
   PubMed Web of Science ®Google Scholar
• AKrag, RWiest, AAlbillos, LLGluud. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012;61:967–9.
   PubMed Web of Science ®Google Scholar
• TSerste, CMelot, CFrancoz, FDurand, PERautou, DValla, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017–22.
   PubMed Web of Science ®Google Scholar
• JFernandez, TGustot. Management of bacterial infections in cirrhosis. J Hepatol 2012;56:S1–12.
   PubMed Web of Science ®Google Scholar
• RWiest, MLawson, MGeuking. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014;60:197–209.
   PubMed Web of Science ®Google Scholar
• CMortensen, JSJensen, LHobolth, SDam-Larsen, BSMadsen, OAndersen, et al. Association of markers of bacterial translocation with immune activation in decompensated cirrhosis. Eur J Gastroenterol Hepatol 2014;26:1360–6.
   PubMed Web of Science ®Google Scholar
• FBendtsen, HGrønbæk, JBHansen, NKAagaard, LSchmidt, SMøller. Treatment of ascites and spontaneous bacterial peritonitis - Part I. Dan Med J 2012;59:C4371.
   PubMed Web of Science ®Google Scholar
• GFede, GD’amico, VArvaniti, ETsochatzis, GGermani, DGeorgiadis, et al. Renal failure and cirrhosis: A systematic review of mortality and prognosis. J Hepatol 2012;56:810–18.
   PubMed Web of Science ®Google Scholar
• PGines, RWSchrier. Renal failure in cirrhosis. N Engl J Med 2009;361:1279–90.
   PubMed Web of Science ®Google Scholar
• FSalerno, AGerbes, PGines, FWong, VArroyo. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut 2007;56:1310–18.
   PubMed Web of Science ®Google Scholar
• FWong, MKNadim, JAKellum, FSalerno, RBellomo, AGerbes, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011;60:702–9.
   PubMed Web of Science ®Google Scholar
• ACardenas, PGines, JUriz, XBessa, JMSalmeron, AMas, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001;34:671–6.
   PubMed Web of Science ®Google Scholar
• LRuiz-Del-Arbol, AMonescillo, CArocena, PValer, PGines, VMoreira, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439–47.
   PubMed Web of Science ®Google Scholar
• SMøller, JHHenriksen, FBendtsen. Central- and non-central blood volumes in cirrhosis. Relation to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol 2003;284:G970–9.
   PubMed Web of Science ®Google Scholar
• SMøller, JSIversen, JHHenriksen, FBendtsen. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol 2007;292:H2966–72.
   PubMed Web of Science ®Google Scholar
• VPStadlbauer, GAWright, MBanaji, AMukhopadhya, RMookerjee, KMoore, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008;134:111–19.
   PubMed Web of Science ®Google Scholar
• SMøller, JHHenriksen. Cirrhotic cardiomyopathy. J Hepatol 2010;53:179–90.
   PubMed Web of Science ®Google Scholar
• SMøller, AKrag. Cardiorenal syndrome - A new entity? In AGerbes, editor. Hyponatremia and hepatorenal syndrome: progress in treatment. Basel: Karger; 2011. p 102–11.
   Google Scholar
• SPiano, FMorando, SFasolato, MCavallin, NBoscato, PBoccagni, et al. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation? J Hepatol 2011;55:491–6.
   PubMed Web of Science ®Google Scholar
• VArroyo, JFernandez. Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 2011;7:517–26.
   PubMed Web of Science ®Google Scholar
• ERodriguez, CElia, ESola, RBarreto, IGraupera, AAndrealli, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol 2014;60:955–61.
   PubMed Web of Science ®Google Scholar
• LESchmidt, HRing-Larsen. Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis. Curr Pharm Des 2006;12:4637–47.
   PubMed Web of Science ®Google Scholar
• LLGluud, KChristensen, EChristensen, AKrag. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576–84.
   PubMed Web of Science ®Google Scholar
• SMøller, JHHenriksen. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001;36:785–94.
   PubMed Web of Science ®Google Scholar
• SMøller. Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis. Thesis Dan Med Bull 1998;45:1–14.
   PubMed Web of Science ®Google Scholar
• SMøller, MBernardi. Interactions of the heart and the liver. Eur Heart J 2013;34:2804–11.
   PubMed Web of Science ®Google Scholar
• EKDahl, SMøller, AKjaer, CLPetersen, FBendtsen, AKrag. Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study. Scand J Gastroenterol 2014;49:362–72.
   PubMed Web of Science ®Google Scholar
• SWiese, JDHove, FBendtsen, SMøller. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 2014;11:177–86.
   PubMed Web of Science ®Google Scholar
• FWong, AVillamil, MMerli, GRomero, PAngeli, PCaraceni, et al. Prevalence of diastolic dysfunction in cirrhosis and its clinical significance. 54 edition. 2011. p 475A.
   Google Scholar
• GFinucci, ADesideri, DSacerdoti, MBolognesi, CMerkel, PAngeli, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996;31:279–84.
   PubMed Web of Science ®Google Scholar
• KKazankov, PHolland-Fischer, NHAndersen, PTorp, ESloth, NKAagaard, et al. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 2011;31:534–40.
   PubMed Web of Science ®Google Scholar
• FSampaio, JPimenta, NBettencourt, RFontes-Carvalho, APSilva, JValente, et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver Int 2013;33:1158–65.
   PubMed Web of Science ®Google Scholar
• TFDowsley, DBBayne, ANLangnas, IDumitru, JRWindle, TRPorter, et al. Diastolic dysfunction in patients with end-stage liver disease is associated with development of heart failure early after liver transplantation. Transplantation 2012;94:646–51.
   PubMed Web of Science ®Google Scholar
• LRuiz-Del-Arbol, LAchecar, RSerradilla, MARodriguez-Gandia, MRivero, EGarrido, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension and a normal creatinine. Hepatology 2013;58:1732–42.
   PubMed Web of Science ®Google Scholar
• SMøller, AKrag, JHHenriksen, FBendtsen. Pathophysiological aspects of pulmonary complications of cirrhosis. Scand J Gastroenterol 2007;42:419–27.
   PubMed Web of Science ®Google Scholar
• JAGrace, PWAngus. Hepatopulmonary syndrome: update on recent advances in pathophysiology, investigation, and treatment. J Gastroenterol Hepatol 2013;28:213–19.
   PubMed Web of Science ®Google Scholar
• SMøller, JHillingsø, EChristensen, JHHenriksen. Arterial hypoxaemia in cirrhosis: fact or fiction? Gut 1998;42:868–74.
   PubMed Web of Science ®Google Scholar
• RRodriguez-Roisin, MJKrowka, PHerve, MBFallon. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24:861–80.
   PubMed Web of Science ®Google Scholar
• SMøller, AKrag, JLMadsen, JHHenriksen, FBendtsen. Pulmonary dysfunction and hepatopulmonary syndrome in cirrhosis and portal hypertension. Liver Int 2009;29:1528–37.
   PubMed Web of Science ®Google Scholar
• JZhang, MBFallon. Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol 2012;130:1136–44.
   Google Scholar
• VIMachicao, MBFallon. Hepatopulmonary syndrome. Semin Respir Crit Care Med 2012;33:11–16.
   PubMed Web of Science ®Google Scholar
• GTKrishnamurthy, SKrishnamurthy. Nuclear hepatology. a textbook of hepatobiliary diseases. Berlin: Springer; 2000.
   Google Scholar
• MJKrowka. Portopulmonary hypertension. Semin Respir Crit Care Med 2012;33:17–25.
   PubMed Web of Science ®Google Scholar
• MJKrowka. Portopulmonary hypertension and the issue of survival. Liver Transpl 2005;11:1026–7.
   PubMed Web of Science ®Google Scholar
• SMKawut, DBTaichman, VNAhya, SKaplan, CLArcher-Chicko, SEKimmel, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005;11:1107–11.
   PubMed Web of Science ®Google Scholar
• TJHollatz, AMusat, SWestphal, CDecker, AMD’Alessandro, JKeevil, et al. Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl 2012;18:686–95.
   PubMed Web of Science ®Google Scholar
• PIversen, MSørensen, LKBak, HSWaagepetersen, MSVafaee, PBorghammer, et al. Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy. Gastroenterology 2009;136:863–71.
   PubMed Web of Science ®Google Scholar
• GDam, SKeiding, OLMunk, POtt, HVilstrup, LKBak, et al. Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake. Hepatology 2013;57:258–65.
   PubMed Web of Science ®Google Scholar
• GWright, YSharifi, MJover-Cobos, RJalan. The brain in acute on chronic liver failure. Metab Brain Dis 2014;29:965–73.
   PubMed Web of Science ®Google Scholar
• TAlmdal, TSchroeder, LRanek. Cerebral blood flow and liver function in patients with encephalopathy due to acute and chronic liver diseases. Scand J Gastroenterol 1989;24:299–303.
   PubMed Web of Science ®Google Scholar
• FSLarsen, KSOlsen, EEjlersen, BAHansen, OBPaulson, GMKnudsen. Cerebral blood flow autoregulation and transcranial Doppler sonography in patients with cirrhosis. Hepatology 1995;22:730–6.
   PubMed Web of Science ®Google Scholar
• RJEde, AESGimson, DBihari, RWilliams. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol 1986;2:43–51.
   PubMed Web of Science ®Google Scholar
• FSLarsen, GMKnudsen, BAHansen. Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure. Tailored cerebral oxygen utilization. J Hepatol 1997;27:231–8.
   PubMed Web of Science ®Google Scholar
• VGFrøkjær, GIStrauss, JMehlsen, GMKnudsen, VRasmussen, FSLarsen. Autonomic dysfunction and impaired cerebral autoregulation in cirrhosis. Clin Auton Res 2006;16:208–16.
   PubMed Web of Science ®Google Scholar
• RJalan, DENewby, SWDamink, DNRedhead, PCHayes, ALee. Acute changes in cerebral blood flow and metabolism during portasystemic shunting. Liver Transpl 2001;7:274–8.
   PubMed Web of Science ®Google Scholar
• ARMani, SMontagnese, CDJackson, CWJenkins, IMHead, RCStephens, et al. Decreased heart rate variability in patients with cirrhosis relates to the presence and severity of hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2008;296:G330–8.
   PubMed Web of Science ®Google Scholar
• HVilstrup, PAmodio, JBajaj, JCordoba, PFerenci, KDMullen, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715–35.
   PubMed Web of Science ®Google Scholar